Reneo Pharmaceuticals, Inc. (RPHM)
Total Valuation
RPHM has a market cap or net worth of $136.88 million. The enterprise value is $37.17 million.
| Market Cap | 136.88M |
| Enterprise Value | 37.17M |
Important Dates
The next earnings date is Monday, May 8, 2023, before market open.
| Estimated Earnings Date | May 8, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
RPHM has 24.53 million shares outstanding. The number of shares has increased by 35.01% in one year.
| Shares Outstanding | 24.53M |
| Shares Change (YoY) | +35.01% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 3.18% |
| Owned by Institutions (%) | 73.80% |
| Float | 9.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 14.01 |
| PB Ratio | 1.37 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.93, with a Debt / Equity ratio of 0.01.
| Current Ratio | 14.93 |
| Quick Ratio | n/a |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -44.10% and return on invested capital (ROIC) is -129.60%.
| Return on Equity (ROE) | -44.10% |
| Return on Assets (ROA) | -40.90% |
| Return on Capital (ROIC) | -129.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.62M |
| Employee Count | 32 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +74.92% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | +74.92% |
| 50-Day Moving Average | 3.74 |
| 200-Day Moving Average | 3.10 |
| Average Volume (30 Days) | 59,291 |
Short Selling Information
The latest short interest is 115,612, so 0.47% of the outstanding shares have been sold short.
| Short Interest | 115,612 |
| Short Previous Month | 95,339 |
| Short % of Shares Out | 0.47% |
| Short % of Float | 1.25% |
| Short Ratio (days to cover) | 1.44 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -53.85M |
| Pretax Income | -51.96M |
| Net Income | -51.96M |
| EBITDA | -51.43M |
| EBIT | -51.96M |
| Earnings Per Share (EPS) | -$2.12 |
Balance Sheet
The company has $101.17 million in cash and $1.46 million in debt, giving a net cash position of $99.71 million or $4.06 per share.
| Cash & Cash Equivalents | 101.17M |
| Total Debt | 1.46M |
| Net Cash | 99.71M |
| Net Cash Per Share | $4.06 |
| Equity / Book Value | 99.97M |
| Book Value Per Share | 4.08 |
| Working Capital | 99.23M |
Cash Flow
In the last 12 months, operating cash flow was -$47.36 million and capital expenditures -$346,000, giving a free cash flow of -$47.71 million.
| Operating Cash Flow | -47.36M |
| Capital Expenditures | -346,000 |
| Free Cash Flow | -47.71M |
| FCF Per Share | -$1.95 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RPHM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -37.96% |
| FCF Yield | -34.86% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -35.01% |
| Shareholder Yield | -35.01% |
Analyst Forecast
The average price target for RPHM is $25.76, which is 361.65% higher than the current price. The consensus rating is "Buy".
| Price Target | $25.76 |
| Price Target Difference | 361.65% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |